Meng L, Wu H, Wu J, Ding Pa, He J, Sang M, et al. Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. Cell Death Dis. 2024;15(1):3. https://doi.org/10.1038/s41419-023-06389-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint Blockade. Science. 2018;359(6382):1350–5. https://doi.org/10.1126/science.aar4060.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801. https://doi.org/10.1038/s41467-020-17670-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-Approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers. 2020;12(3):738.

CAS  PubMed  PubMed Central  Google Scholar 

Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):e002435. https://doi.org/10.1136/jitc-2021-002435.

Article  PubMed  PubMed Central  Google Scholar 

Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and Meta-analysis. JAMA Oncol. 2018;4(12):1721–8. https://doi.org/10.1001/jamaoncol.2018.3923.

Article  PubMed  PubMed Central  Google Scholar 

Thuny F, Bonaca MP, Cautela J. What is the evidence of the diagnostic criteria and screening of immune checkpoint Inhibitor–Induced myocarditis?? JACC: CardioOncology. 2022;4(5):624–8. https://doi.org/10.1016/j.jaccao.2022.06.008.

Article  PubMed  PubMed Central  Google Scholar 

Lehmann LH, Heckmann MB, Bailly G, Finke D, Procureur A, Power JR, et al. Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis. Circulation. 2023;148(6):473–86. https://doi.org/10.1161/circulationaha.123.062405.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2013;34(33):2636–48. https://doi.org/10.1093/eurheartj/eht210.

Article  PubMed  Google Scholar 

Vasbinder A, Chen Y, Procureur A, Gradone A, Azam TU, Perry D, et al. Biomarker trends, incidence, and outcomes of immune checkpoint Inhibitor-Induced myocarditis. JACC CardioOncol. 2022;4(5):689–700. https://doi.org/10.1016/j.jaccao.2022.11.004.

Article  PubMed  PubMed Central  Google Scholar 

Waliany S, Neal JW, Reddy S, Wakelee H, Shah SA, Srinivas S, et al. Myocarditis surveillance with High-Sensitivity troponin I during cancer treatment with immune checkpoint inhibitors. JACC CardioOncol. 2021;3(1):137–9. https://doi.org/10.1016/j.jaccao.2021.01.004.

Article  PubMed  PubMed Central  Google Scholar 

O’Shea MP, Karikalan SA, Yusuf A, Barry T, Habib E, O’Shea J, et al. Complete heart block is a significant predictor of mortality in immune checkpoint inhibitor myocarditis. Cardio-Oncology. 2023;9(1):34. https://doi.org/10.1186/s40959-023-00185-y.

Article  PubMed  PubMed Central  Google Scholar 

Power JR, Alexandre J, Choudhary A, Ozbay B, Hayek S, Asnani A, et al. Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis. Circulation. 2021;144(18):1521–3. https://doi.org/10.1161/circulationaha.121.055816.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international Cardio-Oncology society (IC-OS). Eur Heart J. 2022;43(41):4229–361. https://doi.org/10.1093/eurheartj/ehac244.

Article  PubMed  Google Scholar 

Wang H, Zhao Y, Zhang X, Si X, Song P, Xiao Y, et al. Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study. Cancer Med. 2021;10(1):188–98. https://doi.org/10.1002/cam4.3600.

Article  CAS  PubMed  Google Scholar 

Tamura Y, Tamura Y, Takemura R, Yamada K, Taniguchi H, Iwasawa J, et al. Longitudinal strain and troponin I elevation in patients undergoing immune checkpoint inhibitor therapy. JACC: CardioOncology. 2022;4(5):673–85. https://doi.org/10.1016/j.jaccao.2022.10.007.

Article  PubMed  PubMed Central  Google Scholar 

Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: A JACC white paper. J Am Coll Cardiol. 2009;53(17):1475–87. https://doi.org/10.1016/j.jacc.2009.02.007.

Article  PubMed  PubMed Central  Google Scholar 

Hughes A, Power J, Orimoloye Olusola A, Nowatzke Joseph F, Tamura Y, Aras M, CLINICAL SIGNIFICANCE OF PERICARDIAL EFFUSION IN PATIENTS HOSPITALIZED WITH IMMUNE CHECKPOINT INHIBITOR ASSOCIATED MYOCARDITIS, et al. JACC. 2022;79(9Supplement):1916. https://doi.org/10.1016/S0735-1097(22)02907-2.

Article  Google Scholar 

Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755–64. https://doi.org/10.1016/j.jacc.2018.02.037.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, et al. Global longitudinal strain and cardiac events in patients with immune checkpoint Inhibitor-Related myocarditis. J Am Coll Cardiol. 2020;75(5):467–78. https://doi.org/10.1016/j.jacc.2019.11.049.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Luca G, Palmisano A, Campochiaro C, Vignale D, Cavalli G, Bruno E, et al. Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation. Rheumatology. 2022;61(11):4409–19. https://doi.org/10.1093/rheumatology/keac098.

Article  CAS  PubMed  Google Scholar 

Jia Z, Wang L, Jia Y, Liu J, Zhao H, Huo L, et al. Detection of acute myocarditis using T1 and T2 mapping cardiovascular magnetic resonance: A systematic review and meta-analysis. J Appl Clin Med Phys. 2021;22(10):239–48. https://doi.org/10.1002/acm2.13365.

Article  PubMed  PubMed Central  Google Scholar 

Amano Y, Omori Y, Ando C, Yanagisawa F, Suzuki Y, Tang X, et al. Clinical importance of myocardial T(2) mapping and texture analysis. Magn Reson Med Sci. 2021;20(2):139–51. https://doi.org/10.2463/mrms.rev.2020-0007.

Article  CAS  PubMed  Google Scholar 

O’Brien AT, Gil KE, Varghese J, Simonetti OP, Zareba KM. T2 mapping in myocardial disease: a comprehensive review. J Cardiovasc Magn Reson. 2022;24(1):33. https://doi.org/10.1186/s12968-022-00866-0.

Article  PubMed  PubMed Central  Google Scholar 

Li S, Duan X, Feng G, Sirajuddin A, Yin G, Zhuang B, et al. Multiparametric cardiovascular magnetic resonance in acute myocarditis: comparison of 2009 and 2018 lake Louise criteria with endomyocardial biopsy confirmation. Front Cardiovasc Med. 2021;8. https://doi.org/10.3389/fcvm.2021.739892.

Luetkens JA, Faron A, Isaak A, Dabir D, Kuetting D, Feisst A, et al. Comparison of original and 2018 lake Louise criteria for diagnosis of acute myocarditis: results of a validation cohort. Radiology: Cardiothorac Imaging. 2019;1(3):e190010. https://doi.org/10.1148/ryct.2019190010.

Article  Google Scholar 

Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020;41(18):1733–43. https://doi.org/10.1093/eurheartj/ehaa051.

Article  CAS  PubMed  PubMed Central  Google Scholar